SRT1720通过损害自流来抑制膀癌细胞的进展
Lanlan Li1, Shengjun Fu1, Jianliang Wang2
1Institute of Urology, Key Laboratory of Urological Disease in Gansu Province, Clinical Research Center for Urology in Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Lanzhou 730030, Gansu, China.
Biochemical pharmacology
|March 8, 2024
概括
SRT1720通过诱导亡和阻断自流来抑制膀癌的生长. 这种化合物显示出作为治疗膀癌治疗的新治疗策略的前景,准关键的细胞过程.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 分子医学是分子医学.
背景情况:
- 膀癌 (BC) 存在重大挑战,生存率低,复发率高.
- 目前的治疗方法缺乏针对膀癌的向药物选择.
- 识别新型治疗剂对于改善患者的治疗结果至关重要.
研究的目的:
- 为选抑制膀癌细胞生长的化合物.
- 研究SRT1720在膀癌中的治疗潜力.
- 阐明SRT1720对膀癌细胞的影响背后的分子机制.
主要方法:
- 复合型图书馆查,以确定膀癌细胞生长抑制剂.
- 为了评估SRT1720的疗效,进行了体外和体内研究.
- 对亡,迁移,入侵和自途径的分析.
- 研究蛋白质乙化,特别是LAMP2,作为对SRT1720.20的反应.
主要成果:
- SRT1720显著抑制了膀癌细胞的扩散,迁移和入侵.
- 在膀癌细胞中,SRT1720诱导了亡.
- SRT1720促进了早期的自,但通过阻断自 - 溶酶体融合,抑制了晚期的自.
- SRT1720改变了与自相关的蛋白质表达和乙化,包括LAMP2.2的脱乙化.
结论:
- 在膀癌模型中,SRT1720表现出强大的抗癌作用.
- 通过SRT1720抑制自流是其作用的关键机制.
- 由SRT1720诱导的亡和自流抑制代表了膀癌的潜在新疗法策略.
更多相关视频
09:51Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
Published on: June 30, 2023
828
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.3K
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
